Rivaroxaban Induced Hallucinations: A Case Report
Abstract
Hallucinations induced by rivaroxaban are not much described in literature. This case report describes the occurrence of a specific adverse event during rivaroxaban use in an elderly male who developed hallucinations few months after starting rivaroxaban. Other possible causes for these events were ruled out through comprehensive medical examination. Drug discontinuation led to resolution of adverse drug reaction. The mechanism involved in rivaroxaban-induced hallucinations is not known. The adverse event in our patient was possibly caused by rivaroxaban. Although there is still no strong evidence that can associate hallucinations to rivaroxaban use, and others unknown factors might be involved, this adverse event should be kept in mind when prescribing this drug to older patients.
Downloads
References
Di Cesare M, Jarvis JD, Scarlatescu O, Leng X, Zaidel EJ, et al. NOACs Added to WHO's Essential Medicines List: Recommendations for Future Policy Actions. Glob Heart. 2020;15(1):67. https://doi.org/10.5334/gh.774.
Diagnostic and Statistical Manual of Mental Disorders (DSM V), Fifth Edition, American Psychiatric Association 2013.
Gnoth MJ, Buetehorn U, Muenster U, Schwarz T, Sandmann S. In vitro and in vivo P-glycoprotein transport characteristics of rivaroxaban. J Pharmacol Exp Ther. 2011 Jul;338(1):372-80. https://doi.org/10.1124/jpet.111.180240.
Wang L, He K, Maxwell B, Grossman SJ, Tremaine LM, et al. Tissue distribution and elimination of [14C] apixaban in rats. Drug Metab Dispos. 2011 Feb;39(2):256-64. https://doi.org/10.1124/dmd.110.036442.
Wessler JD, Grip LT, Mendell J, Giugliano RP. The P-glycoprotein transport system and cardiovascular drugs. J Am Coll Cardiol. 2013 Jun 25;61(25):2495-502.
Naranjo CA, Busto U, Sellers EM, Sandor P, Ruiz I, et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther. 1981;30(2):239-45.

Copyright (c) 2022 Anshika Balwan et al.

This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.